General Report Contents
• Market Analyses include: Unit Sales, ASPs, Market Value & Growth Trends
• Market Drivers & Limiters for each chapter segment
• Competitive Analysis for each chapter segment
• Section on recent mergers & acquisitions
Orthopedic biomaterials are associated with high research and development (R&D) costs, which have subsequently led to premium pricing to recoup these initial costs. This is the case for competitors in the cellular allograft, cell therapy and growth factor segments of the U.S. orthopedic biomaterials market. In particular, orthopedic growth factors have had relatively high average selling prices (ASP) since their introduction to the market due to the high costs of recombinant growth factor technologies. The high R&D costs associated with the growth factor segment provide entry barriers against potential competitors. Currently there are only two growth factor BMP-2 products in the United States. Since they’re both used in different indications, there is a lack of direct competition, allowing companies such as Medtronic to charge a premium for the Spine indication and recover the large initial costs associated with R&D. The commoditized nature in some parts of the market, such as the allograft and DBM segments, which is due to the lack of product differentiation, has limited growth. The market is being driven by more competitors venturing outside their traditional space to tap into the high growth segments where they can charge a premium. These segments may include the cell therapy and cellular allograft segments, both of which have relatively high ASP.
'
TABLE OF CONTENTS I
LIST OF FIGURES XVIII
LIST OF CHARTS XIX
EXECUTIVE SUMMARY 1
U.S. ORTHOPEDIC BIOMATERIALS MARKET OVERVIEW 1
COMPETITIVE ANALYSIS 4
MARKET TRENDS 6
MARKET DEVELOPMENTS 8
PROCEDURE NUMBERS 9
MARKETS INCLUDED 11
KEY REPORT UPDATES 13
VERSION HISTORY 13
RESEARCH METHODOLOGY 14
1.1 RESEARCH SCOPE 14
1.2 IDATA’S 9-STEP METHODOLOGY 14
Step 1: Project Initiation & Team Selection 14
Step 2: Prepare Data Systems and Perform Secondary Research 16
Step 3: Preparation for Interviews & Questionnaire Design 17
Step 4: Performing Primary Research 18
Step 5: Research Analysis: Establishing Baseline Estimates 20
Step 6: Market Forecast and Analysis 21
Step 7: Identify Strategic Opportunities 23
Step 8: Final Review and Market Release 24
Step 9: Customer Feedback and Market Monitoring 25
DISEASE OVERVIEW 26
2.1 BASIC ANATOMY 26
2.1.1 Osteology and Musculoskeletal System 26
2.2 DISEASE PATHOLOGY AND DISORDERS 28
2.2.1 General Diagnostic 28
2.2.2 Osteoporosis 29
2.2.3 Osteoarthritis 29
2.2.4 Indication for Bone Graft Procedure 30
2.2.5 Indication for Cartilage Repair 31
2.2.6 Degenerative Disc Disease 32
2.3 PATIENT DEMOGRAPHICS 34
2.3.1 General Statistics 34
U.S. ORTHOPEDIC BIOMATERIALS MARKET OVERVIEW 36
3.1 INTRODUCTION 36
3.1.1 Bone Graft Substitutes 36
3.1.2 Growth Factors 37
3.1.3 Cellular Allograft 37
3.1.4 Cell Therapies 38
3.1.5 Hyaluronic Acid Viscosupplementation 38
3.1.6 Cartilage Repair 38
3.1.7 Spinal Machined Bone Allografts 39
3.2 MARKET OVERVIEW 40
3.3 TREND ANALYSIS BY SEGMENT 45
3.4 DRIVERS AND LIMITERS 48
3.4.1 Market Drivers 48
3.4.2 Market Limiters 49
3.5 MERGERS AND ACQUISITIONS 51
3.6 COMPETITIVE MARKET SHARE ANALYSIS 54
3.7 COMPANY PROFILES 64
3.7.1 Anika Therapeutics 64
3.7.2 Bioventus 65
3.7.3 DePuy Synthes 66
3.7.4 Ferring Pharmaceuticals 67
3.7.5 Fidia Pharmaceuticals 68
3.7.6 Genzyme (Sanofi Group) 69
3.7.7 Harvest Technologies (Terumo BCT) 70
3.7.8 Integra LifeSciences 71
3.7.9 Medtronic 72
3.7.10 Musculoskeletal Transplant Foundation (MTF) 74
3.7.11 NuVasive 75
3.7.12 Orthofix 76
3.7.13 RTI Surgical 77
3.7.14 Vericel Corporation (formerly Aastrom Bioscience) 78
3.7.15 Stryker 79
3.7.16 Zimmer Biomet 80
ABBREVIATIONS 82
APPENDIX II: COMPANY PRESS RELEASES 84
Chart 1 1: Orthopedic Biomaterials Market by Segment, U.S., 2013 – 2023 3
Chart 1 2: Orthopedic Biomaterials Market Overview, U.S., 2016 & 2023 3
Chart 3 1: Orthopedic Biomaterials Market by Segment, U.S., 2013 – 2023 43
Chart 3 2: Orthopedic Biomaterials Market Breakdown, U.S., 2016 44
Chart 3 3: Orthopedic Biomaterials Market Breakdown, U.S., 2023 44
Chart 3 4: Growth Rates by Segment, Orthopedic Biomaterials Market, U.S., 2013 – 2023 47
Chart 3 5: Leading Competitors, Orthopedic Biomaterials Market, U.S., 2016 63
MedtronicGenzymeDePuy SynthesAnika TherapeuticsFerring PharmaceuticalsStrykerNuVasiveBioventusZimmer BiometIntegra LifeSciencesRTI SurgicalFidia PharmaceuticalsMTFOrthofixArthrexAlloSourceAastromBaxterHarvest TechnologiesWright MedicalBacterin InternationalArteriocyteExactechLifeNet HealthBiocompositesAlphatec SpineCelling BiosciencesGlobus MedicalNuo TherapeuticsK2M*Not all companies are currently active in every segment or sub-report from this suite. For more details contact an iData Research Product Advisor.